GlassScriptPhysician profile
John Michael Kelley
NPI 1538549720
$1,093.95
in general payments reported to CMS, 2019-2025
24 companies · $315 in 2025
The $315 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $39.85 · 2021: $384 · 2022: $234 · 2023: $44.12 · 2024: $77.53 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $437.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $436.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $202.41 | 2025 | |
| Abbvie INC. | $119.77 | 2021-2022 | |
| Esperion Therapeutics, INC. | $87.33 | 2020-2022 | |
| Scpharmaceuticals INC. | $83.60 | 2025 | |
| Lilly USA, LLC | $76.97 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.85 | 2022 | |
| Novo Nordisk INC | $47.22 | 2022 | |
| Amgen INC. | $45.10 | 2023-2024 | Repatha |
| Genentech USA, INC. | $38.88 | 2021-2024 | Xolair |
| Pulmonx Corporation | $33.83 | 2024 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Amarin Pharma, INC. | $33.66 | 2021 | |
| Kaleo, INC. | $33.35 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $31.93 | 2021 | |
| Galderma Laboratories, L.P. | $28.96 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.36 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23.57 | 2022 | |
| Bioxcel Therapeutics, INC. | $21.62 | 2023 | Igalmi |
| Antares Pharma, INC. | $18.78 | 2021 | |
| Nestle Healthcare Nutrition INC. | $17.39 | 2021 | |
| Cranial Technologies, INC | $16.55 | 2021 | |
| Daiichi Sankyo INC. | $15.46 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.42 | 2022 | |
| Pfizer INC. | $13.59 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $13.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.